| Literature DB >> 35308493 |
Lin-Chieh Meng1, Shih-Tsung Huang1, Li-Ning Peng2,3, Liang-Kung Chen2,3,4, Fei-Yuan Hsiao1,5,6.
Abstract
Introduction: This study aims to develop and validate an integrative intrinsic capacity (IC) scoring system, to investigate its associations with a wide spectrum of biomarkers and to explore the predictive value of the integrative IC score on 4-year mortality among community dwelling people aged 50 years and older.Entities:
Keywords: biomarkers; genetic markers; healthy aging; intrinsic capacity; mortality
Year: 2022 PMID: 35308493 PMCID: PMC8931213 DOI: 10.3389/fmed.2022.851882
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Development and validation of scoring system for intrinsic capacity using multivariate logistic regression model.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
|
| |||||
| Slowness (Q1) | – | – | – | – | 0 |
| Robust (Q2–Q5) | 0.42 | 0.23–0.76 | <0.01 | −0.87 | 1 |
|
| |||||
| Slowness (Q1) | – | – | – | – | 0 |
| Robust (Q2–Q5) | 0.19 | 0.11–0.35 | <0.01 | −1.64 | 2 |
|
| |||||
|
| |||||
| With visual impairment | – | – | – | – | 0 |
| Without visual impairment | 0.79 | 0.48–1.32 | 0.37 | −0.23 | 1 |
|
| |||||
| With hearing loss | – | – | – | – | 0 |
| Without hearing loss | 0.77 | 0.26–2.32 | 0.65 | −0.26 | 1 |
|
| |||||
|
| |||||
| Malnutrition | – | – | – | – | 0 |
| Normal BMI | 0.70 | 0.42–1.07 | 0.09 | −0.40 | 1 |
|
| |||||
| Weakness (male <28 kg, female <18 kg) | – | – | – | – | 0 |
| Robust (male ≧ 28 kg, female ≧ 18 kg) | 0.32 | 0.19–0.53 | <0.01 | −1.15 | 1 |
|
| |||||
|
| |||||
| Depression (>8) | – | – | – | – | 0 |
| Wellbeing (≦8) | 0.22 | 0.12–0.39 | <0.01 | −1.52 | 2 |
|
| |||||
| Higher level of stress (≧14) | – | – | – | – | 0 |
| Lower level of stress (<14) | 0.61 | 0.36–1.03 | 0.06 | −0.50 | 1 |
|
| |||||
|
| |||||
| Cognitive impairment (≧3) | – | – | – | – | 0 |
| Cognitive health (<3) | 0.33 | 0.15–0.71 | <0.01 | −1.11 | 1 |
|
| |||||
| Cognitive impairment (≦5) | – | – | – | – | 0 |
| Cognitive health (>5) | 0.32 | 0.10–1.01 | 0.05 | −1.13 | 1 |
OR, Odds ratio; CI, confidence interval; BMI, Body mass index; CES-D-10, 10-item Center for Epidemiologic Studies Depression; PSS-10, 10-item Perceived Stress Scale; SPMSQ, Short Portable Mental State Questionnaire; MMSE, Mini-Mental State Examination.
AUROC: Derivation = 0.831, Validation = 0.858.
Hosmer-Lemeshow test: Derivation p = 0.173, Validation p = 0.143.
Comparison of characteristics and biomarkers according to intrinsic capacity tertiles.
|
| ||||
|---|---|---|---|---|
|
|
|
|
| |
| Number | 367 | 257 | 215 | |
| Sex (female) | 140 (38.2%) | 120 (46.7%) | 120 (55.8%) | <0.01 |
| Age (year) | 61.7 ± 7.5 | 64.6 ± 8.9 | 72.2 ± 9.0 | <0.01 |
| <60 | 191 (52.0%) | 106 (41.2%) | 30 (14.0%) | |
| 60–64 | 70 (19.1%) | 35 (13.6%) | 13 (6.0%) | |
| 65–74 | 72 (19.6%) | 66 (25.7%) | 73 (34.0%) | |
| 75–84 | 30 (8.2%) | 45 (17.5%) | 79 (36.7%) | |
| ≧85 | 4 (1.1%) | 5 (2.0%) | 20 (9.3%) | |
| The level of education | <0.01 | |||
| No schooling | 24 (6.5%) | 41 (16.0%) | 68 (31.6%) | |
| Elementary | 161 (43.9%) | 114 (44.3%) | 92 (42.8%) | |
| Junior/senior high | 114 (31.1%) | 66 (25.7%) | 45 (20.9%) | |
| College/graduate school | 68 (18.5%) | 36 (14.0%) | 10 (4.7%) | |
| Smoking status | 0.33 | |||
| No | 300 (81.7%) | 201 (78.2%) | 183 (85.1%) | |
| Sometimes | 7 (1.9%) | 5 (2.0%) | 5 (2.3%) | |
| Frequently | 60 (16.4%) | 51 (19.8%) | 27 (12.6%) | |
| Comorbidities | 1.6 ± 1.6 | 2.0 ± 1.8 | 3.2 ± 2.0 | <0.01 |
| Socioeconomic status | 4.7 ± 1.7 | 4.3 ± 1.8 | 4.1 ± 1.8 | <0.01 |
|
| ||||
|
| ||||
| Gait speed (m/s) | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.6 ± 0.2 | <0.01 |
| Chair stand (s/5 stands) | 8.7 ± 2.2 | 10.5 ± 4.1 | 15.3 ± 5.3 | <0.01 |
|
| ||||
| Visual acuity | 0.8 ± 0.3 | 0.6 ± 0.4 | 0.5 ±0.3 | <0.01 |
| Hearing loss | 1 (0.3%) | 5 (2.0%) | 17 (7.9%) | <0.01 |
|
| ||||
| Body mass index (kg/m2) | 24.4 ± 2.9 | 25.2 ± 3.5 | 25.4 ± 4.0 | <0.01 |
| Grip strength (kg) | ||||
| Male | 37.2 ± 7.2 | 33.1 ± 7.7 | 26.4 ± 8.3 | <0.01 |
| Female | 22.8 ± 5.3 | 22.1 ± 12.5 | 15.7 ± 5.9 | <0.01 |
|
| ||||
| CES-D-10 (0–30) | 2.2 ± 2.5 | 4.4 ± 4.8 | 8.1 ± 6.7 | <0.01 |
| PSS-10 (0–40) | 7.8 ± 5.1 | 10.7 ± 6.5 | 11.4 ±7.2 | <0.01 |
|
| ||||
| SPMSQ (0–10) | 1.2 ± 0.4 | 1.4 ± 0.7 | 1.9 ± 1.1 | <0.01 |
| MMSE (language and recall, 0–6) | 6.0 ± 0.0 | 6.0 ± 0.2 | 5.8 ± 0.6 | <0.01 |
|
| ||||
| Systolic blood pressure (mm Hg) ( | 125.1 ± 18.8 | 129.0 ± 19.0 | 136.2 ± 21.6 | <0.01 |
| Diastolic blood pressure (mm Hg) ( | 74.2 ± 10.1 | 72.9 ± 10.5 | 72.5 ± 11.1 | 0.13 |
| Total cholesterol (mg/dL) | 200.1 ± 38.5 | 200.5± 38.1 | 198.1 ± 37.9 | 0.77 |
| HDL cholesterol (mg/dL) | 47.7 ± 14.1 | 48.9 ± 13.4 | 47.7 ± 13.9 | 0.49 |
| Triglycerides (mg/dL) | 111.5 ± 67.4 | 112.1 ± 72.5 | 119.5 ± 71.6 | 0.37 |
| Glycosylated hemoglobin (%) | 6.0 ± 1.1 | 6.2 ± 1.2 | 6.3 ± 1.3 | 0.02 |
| Fasting glucose (mg/dL) | 103.9 ± 25.9 | 108.4 ± 32.0 | 110.5 ± 35.3 | 0.03 |
| Waist-to-hip ratio ( | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | <0.01 |
| Homocysteine (μmol/L) ( | 11.2 ± 4.7 | 11.3 ± 4.6 | 13.2 ± 5.6 | <0.01 |
|
| ||||
| DHEA-S (μg/dL) | 122.1 ± 75.9 | 114.6 ± 71.3 | 83.6 ± 60.0 | <0.01 |
| IGF-1 (nmol/L) | 162.6 ± 64.9 | 147.6 ± 60.0 | 133.9 ± 56.8 | 0.04 |
| Urine Cortisol (μg/g creatinine) ( | 17.9 ± 27.9 | 18.7 ± 20.1 | 23.0 ± 45.5 | 0.15 |
| Urine Epinephrine (μg/g creatinine) ( | 3.9 ± 2.6 | 3.9 ± 2.3 | 4.6 ± 2.9 | <0.01 |
| Urine Norepinephrine (μg/g creatinine) ( | 25.9 ± 12.2 | 27.5 ± 13.1 | 29.0 ± 16.4 | 0.03 |
| Urine Dopamine (μg/g creatinine) ( | 176.8 ± 66.0 | 184.1 ± 69.0 | 216.5 ± 623.6 | 0.34 |
|
| ||||
| White blood cell count (109 /L) ( | 6.0 ± 1.7 | 6.1 ± 1.7 | 6.3 ± 1.8 | 0.04 |
| Neutrophils (%) ( | 57.0 ± 10.1 | 58.5 ± 9.3 | 58.9 ± 10.1 | 0.04 |
| Interleukin-6 (pg/mL) | 3.3 ± 6.8 | 3.3 ± 4.4 | 4.9 ± 7.6 | <0.01 |
| Creatinine (mg/dL) | 0.9 ± 0.2 | 0.9 ± 0.3 | 1.1 ± 0.6 | <0.01 |
| sICAM-1(ng/ml) | 254.2 ± 80.5 | 264.7 ± 84.9 | 291.6 ± 105.1 | <0.01 |
| Fibrinogen (mg/dL) | 323.5 ± 61.5 | 330.0 ± 70.0 | 344.8 ± 70.3 | 0.01 |
| hsCRP (mg/dl) | 0.2 ± 0.3 | 0.3 ± 0.7 | 0.3 ± 0.7 | <0.01 |
| E-selectin (ng/mL) | 38.3 ± 26.4 | 43.2 ± 30.7 | 44.2 ± 27.0 | 0.02 |
| sIL-6R (ng/mL) | 41.1 ± 11.4 | 43.1 ± 12.4 | 43.4 ± 13.0 | 0.04 |
| Albumin (g/dL) | 4.5 ± 0.3 | 4.5 ± 0.3 | 4.4 ± 0.3 | <0.01 |
| Folate (ng/mL) | 9.4 ± 6.1 | 9.2 ± 5.5 | 10.1 ± 9.8 | 0.30 |
| Allostatic load (0–12) ( | 3.6 ± 2.1 | 3.7 ± 2.2 | 4.5 ± 2.3 | <0.01 |
|
| ||||
| APOE ε4 carrier ( | 49 (13.4%) | 37 (14.6%) | 38 (17.7%) | 0.37 |
| 5-HTTLPR ( | 0.63 | |||
| S/S | 167 (45.9%) | 116 (46.2%) | 93 (44.1%) | |
| S/L | 128 (35.2%) | 94 (37.5%) | 86 (40.8%) | |
| S/XL | 21 (5.8%) | 17 (6.8%) | 13 (6.2%) | |
| L/L or L/XL | 48 (13.2%) | 24 (9.6%) | 19 (9.0%) | |
CES-D-10, 10-item Center for Epidemiologic Studies Depression; PSS-10, 10-item Perceived Stress Scale; SPMSQ, Short Portable Mental State Questionnaire; MMSE, Mini-Mental State Examination; DHEA-S, Dehydroepiandrosterone sulfate; IGF-1, Insulin-like growth factor-1; sICAM-1, Soluble intercellular adhesion molecule-1; hsCRP, high sensitivity C- reactive protein; sIL-6R, Soluble IL-6 receptor; APOE, Apolipoprotein E; 5-HTTLPR, The Serotonin Transporter Polymorphism.
Comorbidities = self-report physician diagnosed chronic conditions, including hypertension, diabetes, heart disease, stroke, cancer, pulmonary disease, gastric disease, liver disease, arthritis, kidney disease, gout, cataract, degenerative joint disease, spinal/vertebrae spur, and hip fracture.
Figure 1Forest plot for ordinary logistic regression examining the association between biomarkers and intrinsic capacity (IC) groups (from low IC to high IC). Adjust for age, sex, level of education, smoking status, socioeconomic status, and number of comorbidities. (A) Total study subjects (aged ≧ 50). (B) Subgroup analysis (aged ≧ 60). OR, Odds ratio; CI, Confidence interval; DHEA-S, Dehydroepiandrosterone sulfate; IGF-1, Insulin-like growth factor-1; sICAM-1, Soluble intercellular adhesion molecule-1; hsCRP, high sensitivity C- reactive protein; sIL-6R, Soluble IL-6 receptor; APOE, Apoliprotein E; 5-HTTLPR, The Serotonin Transporter Polymorphism.
Figure 2Kaplan-Meier survival curve by tertiles of intrinsic capacity. (A) Total study subjects (aged ≧ 50). (B) Subgroup analysis (aged ≧ 60).
Tertiles of intrinsic capacity (IC) and 4-year mortality.
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| High IC |
| – | – |
| – | – |
| – | – |
| Medium IC | 1.05 | 0.48–2.28 | 0.91 | 0.92 | 0.42–2.03 | 0.83 | 0.84 | 0.38–1.88 | 0.67 |
| Low IC | 4.88 | 2.69–8.85 | <0.01 | 3.02 | 1.52–6.00 | <0.01 | 2.50 | 1.22–5.11 | 0.01 |
| High IC |
| – | – |
| – | – |
| – | – |
| Medium IC | 0.80 | 0.34–1.87 | 0.60 | 0.81 | 0.34–1.93 | 0.64 | 0.73 | 0.30–1.76 | 0.52 |
| Low IC | 2.89 | 1.53–5.45 | <0.01 | 2.63 | 1.30–5.36 | <0.01 | 2.19 | 1.03–4.64 | 0.04 |
HR, Hazard ratio; CI, Confidence interval.
Model 1: adjust for age, sex, level of education, smoking status, socioeconomic status, and number of comorbidities.
Model 2: adjust for age, sex, level of education, smoking status, socioeconomic status, number of comorbidities and biomarkers (e.g., IL-6, E-selectin, albumin and folate for total study subjects; IL-6, albumin, folate and APOE gene for subgroup analysis).